Multiple myeloma trials in Japan

In Japan 34 Also abroad 704

34 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Where
Chiba, Fukushima, Iruma-gun, Kamogawa, Kashiwa-shi, Kita-ku, Kofu, Kumamoto, Kurume, Maebashi, Nagakute, Ōgaki, Sapporo, Sendai, Shibukawa, Shibuya-ku, Shiwa-gun, Suita-shi, Tokushima
Age
18 years and over
People
410 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00
Phase 3Taking people
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Where
Kofu, Matsumoto-shi, Nagoya, Okayama, Tokushima
Age
18 years and over
People
270 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07393282 · EU 2025-523252-31-00
Phase 2Taking people
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Chiba, Fukuoka, Gifu, Hokkaido, Kobe, Koshigaya, Kumamoto, Kurashiki, Matsumoto, Okayama, Osaka, Ōtake, Shiwa-gun
Age
18 years and over
People
510 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00
Phase 4Taking people
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Where
Nagoya, Shibuya City
Age
18 years and over
People
295 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00
Phase 3Taking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Bunkyō City, Chiba, Higashiibaraki-gun, Hirakata, Hyōgo, Iruma-gun, Kanagawa, Kanazawa, Kumamoto, Matsuyama, Nagasaki, Okayama, Osaka, Sapporo, Shibukawa, Shibuya-ku, Sunto-gun, Toyoake, Yamagata, Yamanashi
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 1Taking people
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Where
Shibuya City, Suita-shi, Tokyo
Age
18 years and over
People
180 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00
Phase 3Taking people
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Where
Bunkyō City, Chiba, Kamakura-shi, Kamogawa, Kofu, Minato, Shibuya City, Yokohama
Age
18 years and over
People
400 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00
Phase 3Taking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Chiba, Fukuoka, Higashiibaraki, Hiroshima, Iruma, Kamakura, Kashiwa, Kitakyushu-shi, Koshigaya, Kumamoto, Nagaizumi-cho,Sunto-gun, Nagasaki, Sapporo, Shibuya-ku, Shiwa-gun Yahaba-cho, tabashi City, Tokyo
Age
18 years and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
Phase 1/2Taking people
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Where
Kashiwa, Nagoya, Yamagata
Age
18 years and over
People
226 worldwide
Run by
AstraZeneca
See details and how to joinNCT06106945 · EU 2023-508590-89-00
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Fukuoka, Kanazawa, Kashiwa, Kumamoto, Nagoya, Nishinomiya, Okayama, Osaka, Shibuya-ku, Yamagata
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 3Taking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Fukuoka, Maebashi, Nagaizumi-chō, Okayama, Osaka, Sendai, Shibuya-ku, Yahaba-cho, Yamagata, Yoshida-gun
Age
18 years and over
People
1,060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Kyoto, Nagoya, Shibuya-ku, Suita-shi, Tokyo
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00
Phase 1/2Taking people
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Where
Hidaka, Kasama-Shi, Kashiwa-shi, Kyoto, Maebashi, Nagoya, Shibuya-ku, Tokushima, Tokyo
Age
18 years and over
People
387 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT03761108 · EU 2024-511454-45-00
Phase 3Taking people
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Where
Nagoya
Age
18 years to 130 years
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07735637
Phase 1Taking people
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Aichi, Okayama, Tokyo, Yamagata
Age
18 years and over
People
186 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00
Phase 1Taking people
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Where
Bunkyo Ku, Koto-ku
Age
18 years and over
People
127 worldwide
Run by
AbbVie
See details and how to joinNCT07409246
Phase 1/2Taking people
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Where
Kyoto, Nagoya, Shibuya-ku, Suita-shi
Age
18 years to 64 years
People
602 worldwide
Run by
AbbVie
See details and how to joinNCT06892522 · EU 2024-515770-27-00
Phase 2/3Taking people
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Where
Isehara, Kurume-shi, Kyoto, Matsuyama, Nagoya
Age
18 years and over
People
680 worldwide
Run by
AbbVie
See details and how to joinNCT07095452 · EU 2025-520897-21-00
Phase 2Enrolling by invitation
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Where
Okayama
Age
18 years and over
People
70 worldwide
Run by
Sanofi
See details and how to joinNCT05669989
Phase 3Taking people
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Where
Aichi, Ehime, Gunma, Hyōgo, Kyoto, Numakunai, Okayama, Osaka, Saitama, Shibuya-ku, Tokyo, Toyohashi, Yamagata
Age
18 years and over
People
380 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00
Phase 2Taking people
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Where
Chiba, Kyoto, Nagoya, Nishinomiya, Shibuya-ku
Age
18 years and over
People
230 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06297226
Phase 3Taking people
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Where
Bunkyō City, Kashiwa, Kyoto, Nagoya, Shibuya-ku, Shinjuku-ku
Age
18 years and over
People
508 worldwide
Run by
AstraZeneca
See details and how to joinNCT07391657
Phase 3Taking people
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Chiba, Fukuoka, Gunma, Kamakura-shi, Kyoto, Matsuyama, Okayama, Sapporo, Tokyo, Yokohama
Age
18 years and over
People
700 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07518186
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Where
Aichi, Chiba, Ehime, Fukushima, Gunma, Hokkaido, Ishikawa, Numakunai, Okayama, Osaka, Sendai, Tokyo, Yamanashi
Age
18 years and over
People
200 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07227311 · EU 2025-523117-28-00
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Akita, Fukuoka, Kagoshima, Kumamoto, Nagasaki, Nagoya, Okayama, Osaka, Sendai, Shibukawa, Shibuya-ku, Sunto-gun, Tokushima, Yahaba-cho, Yamagata, Yoshida-gun
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00